我国肿瘤治疗费用核算与筹资负担分析

Analysis of Cost Accounting and Financing Burden of Tumor Treatment in China

目的:为我国肿瘤防治政策和筹资机制调整提供数据支撑。方法:基于“卫生费用核算体系2011”,核算2018年我国肿瘤治疗费用情况。结果:2018年我国肿瘤治疗费用3924.62亿元;服务分布上,87.53%的费用发生在住院;病种分布上,83.44%的费用用于癌症治疗,主要是肺癌、乳房恶性肿瘤、胃癌、肝癌等;机构流向上,72.53%的费用流向综合医院;年龄分布上,72.79%的费用集中在45~74岁人群;筹资来源上,公共筹资方案占62.76%,家庭卫生支出占27.48%。结论:肿瘤发病趋势将带来治疗费用的持续增长,要建立合理的筹资机制,增加筹资总量,优化资金存量,合理支出结构,以达到更好的肿瘤防治效果。

Objective To provide data support for the adjustment of tumor prevention and treatment policy and financing mechanism in China.Methods Based on the Health Cost Accounting System 2011,the cost of tumor treatment in China in 2018 was calculated.Results In 2018,the cost of tumor treatment in China was 392.462 billion yuan;in terms of service distribution,87.53% of the expenses were incurred in hospitalization;in the distribution of diseases,83.44% of the expenses were spent on cancer treatment,mainly lung cancer,breast malignant tumors,gastric cancer,liver cancer,etc.;in the flow direction of institutions,72.53% of the expenses went to general hospitals;in terms of age distribution,72.79% of the expenses were concentrated in people aged 45 to 74 years old.In terms of financing sources,public financing plan accounted for 62.76%,and household health expenditure accounted for 27.48%.Conclusion The trend of tumor incidence will lead to the continuous increase of treatment costs.It is necessary to establish a reasonable financing mechanism,increase the total amount of financing,optimize the stock of funds and reasonable expenditure structure in order to achieve a better effect of tumor prevention and treatment.